Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 225.10 -5.61 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $230.71 | 52 Week High | $109.10 | |||
| Open | $227.86 | 52 Week Low | $31.38 | |||
| Day High | $230.84 | P/E | N/A | |||
| Day Low | $224.88 | EPS | $-1.45 | |||
| Volume | 1,181,022 | |||||
